Prolato Clinical Research Center | Houston, TX

Research site
8990 Kirby Drive Suite 240, Houston, Texas, United States of America
Site insights

Top conditions

Kidney Diseases (13 trials)

IGA Glomerulonephritis (5 trials)

Focal Segmental Glomerulosclerosis (4 trials)

Nephritis (3 trials)

Chronic Renal Insufficiency (3 trials)

Top treatments

BI 764198

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


17 of 24
Status: Active
Trial type: Interventional
Funder type: Industry

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this b...

Active, not recruiting
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (Semaglutide)

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Primary IgA Nephropathy
Drug: LNP023

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...

Active, not recruiting
Primary Membranous Nephropathy
Drug: Diphenhydramine
Drug: Acetaminophen

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have fail...

Systemic Lupus Erythematosus
Lupus Erythematosus
Drug: Imvotamab

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with...

Systemic Lupus Erythematosus
Drug: Methylprednisolone
Drug: Acetaminophen/Paracetamol

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in...

Primary IgA Nephropathy
Drug: Placebo
Drug: RO7434656

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Primary Membranous Nephropathy
Drug: Zanubrutinib
Drug: Tacrolimus

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out...

Kidney Disease, Chronic
Drug: Placebo
Drug: BI 764198

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment in 2 months
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: Atrasentan

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular d...

Active, not recruiting
Immunoglobulin A Nephropathy
Alport Syndrome
Drug: Atrasentan

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Proteinuric Kidney Disease
Drug: VX-147
Drug: Placebo

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: Placebo Multiple Doses
Drug: BION-1301 Single Dose

The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.

Glomerular Disease
Drug: Placebo
Drug: ANG-3070

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with activ...

Sjogren Syndrome
Biological: VAY736
Other: Placebo

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Chronic Kidney Disease
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial sponsors

Novartis logo

Novartis (3 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems